Beijing Sun-Novo Pharmaceutical Research Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Yujing Liu
Chief executive officer
CN¥2.3m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 5yrs |
| CEO ownership | 4.1% |
| Management average tenure | 5.5yrs |
| Board average tenure | 5yrs |
Recent management updates
Recent updates
CEO
Yujing Liu (42 yo)
5yrs
Tenure
CN¥2,250,100
Compensation
Mr. Yujing Liu serves as Director and General Manager at Beijing Sun-Novo Pharmaceutical Research Co.,Ltd. since March 2020.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Director | 5yrs | CN¥2.25m | 4.06% CN¥ 203.9m | |
| CFO, Board Secretary | no data | CN¥1.04m | 0.54% CN¥ 27.0m | |
| Deputy General Manager | 5yrs | CN¥1.16m | 2.25% CN¥ 112.9m | |
| Deputy GM & Core Technician | 5yrs | CN¥1.11m | no data | |
| Deputy GM & Core Technician | 5yrs | CN¥1.32m | no data | |
| Deputy General Manager | 6.9yrs | CN¥938.21k | no data | |
| Core Technical Staff | 6.1yrs | CN¥452.10k | no data | |
| Core Technical Staff | 7.8yrs | CN¥917.00k | no data | |
| Core Technical Staff | 6.8yrs | CN¥355.30k | no data |
5.5yrs
Average Tenure
43yo
Average Age
Experienced Management: 688621's management team is seasoned and experienced (5.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Director | 5yrs | CN¥2.25m | 4.06% CN¥ 203.9m | |
| CFO, Board Secretary | 5yrs | CN¥1.04m | 0.54% CN¥ 27.0m | |
| Director | 5yrs | no data | no data | |
| Independent Director | 5yrs | CN¥120.00k | no data | |
| Director | 5yrs | no data | no data | |
| Chairman of the Board | 5yrs | CN¥1.50m | 27.59% CN¥ 1.4b | |
| Director | 5yrs | no data | no data | |
| Chairman of the Supervisory Board | 5yrs | no data | no data | |
| Employee Representative Supervisor | 5yrs | no data | no data | |
| Supervisor | 2yrs | no data | no data | |
| Independent Director | 2yrs | no data | no data |
5.0yrs
Average Tenure
42yo
Average Age
Experienced Board: 688621's board of directors are considered experienced (5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/23 18:56 |
| End of Day Share Price | 2025/03/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yinglan Shu | Haitong International Research Limited |
| Hanyang Huang | Industrial Securities Co. Ltd. |
| Jiaqi Zhu | Zhongtai Securities Co. Ltd. |